The Wegovy dose range: what each step is for and why it matters

You've just started Wegovy, and the first pen feels underwhelming

That is by design. The 0.25mg weekly injection is not a therapeutic dose; its job is to introduce semaglutide to your body gradually, keeping nausea and gut discomfort manageable while your system adapts. Most people notice very little appetite change at this stage, which can feel frustrating. Stick with it.

After roughly four weeks on 0.25mg, the schedule moves to 0.5mg, a step that marks the first meaningful increase and one many people find more noticeable than the starting injection, then 1.0mg, then 1.7mg, each step held for about a month. By the time you reach 2.4mg, which was until recently the standard maintenance dose for weight management, appetite suppression and satiety effects are typically well established. The full Wegovy dose ladder explains each step in more detail, including what most people experience at each level.

The titration exists for a reason beyond comfort. Trial evidence shows that dose-related gastrointestinal side effects (nausea, loose stools, reflux, reduced appetite to the point of undereating) are most likely at or just after a step-up. Slowing the climb reduces that risk. If side effects are significant at any stage, your prescriber may hold you at the current dose for longer before moving up. That is not a setback; it is the process working correctly.

Keep the pen in the fridge door alongside anything else you refrigerate weekly, it is a practical prompt that the injection is part of a routine, not a separate medical event.

The dose range now extends beyond 2.4mg, here is what changed

In January 2026 the MHRA approved a 7.2mg maintenance dose for Wegovy, supplied initially as three 2.4mg pens per week. On 14 April 2026 a dedicated single-dose 7.2mg pen was approved, designed to deliver the full weekly amount in one pre-set injection, with an auto-dosing mechanism and a covered needle that locks after use. The MHRA announcement confirmed this pen is licensed for adults with a BMI of 30 or above, and is not approved for the cardiovascular indication or for lower BMI thresholds.

The starting dose remains 0.25mg regardless of which maintenance dose a patient is working towards. Titration still runs in roughly four-week increments through the intermediate steps before reaching 7.2mg. Trial data at this higher dose showed average weight loss of around 20.7% over 72 weeks, approaching the results seen with tirzepatide 15mg in the SURMOUNT programme, though direct head-to-head comparisons are not straightforward, and a prescriber's choice between medicines reflects your individual health picture, not just a percentage figure.

If you are curious how Wegovy compares with other licensed weight-management injections, the Wegovy overview sets out the evidence alongside what is known about tirzepatide.

One practical note: whether the 7.2mg pen format is the right fit for a given patient is something a prescriber confirms at assessment. Specific dose and pen availability is confirmed at consultation, not assumed in advance.

Who the full dose range applies to, and where the upper limit sits

The licensed eligibility for Wegovy in the UK covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. The 7.2mg pen carries a tighter restriction: BMI of 30 or above only, not the 27-plus-comorbidity threshold.

NICE's appraisal of semaglutide for weight management (TA875) recommends NHS access within specialist weight management services for a maximum of two years, with stopping rules if weight loss is under 5% after six months on the maintenance dose. Private prescribing follows the licensed criteria rather than the NHS commissioning thresholds, so the eligibility picture is somewhat different. The cost context for Wegovy is worth reading alongside eligibility if you are weighing up the private route.

Lower BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK clinical guidance, typically 2.5 kg/m² lower at each threshold. A prescriber factors this in during assessment alongside your full health history, not as a tick-box calculation.

For a closer look at how individual pen strengths within the range work, the pen dose guide covers the mechanics of each injector format.

Side effects across the dose range, and when to get medical help

Gastrointestinal effects are the most common across every dose level: nausea, constipation, loose stools, reflux, burping and reduced appetite. They tend to peak in the first week or two after each step-up and ease as your body adjusts. Most people find them manageable; some find them significant enough to pause titration. That conversation belongs with your prescriber, not a forum.

Seek urgent medical attention if you develop severe stomach pain that radiates to your back, with or without vomiting, this can be a sign of acute pancreatitis, which the MHRA identified in a Drug Safety Update in January 2026 as a known but infrequent serious risk with GLP-1 medicines. Other reasons to contact a clinician promptly include signs of a serious allergic reaction, symptoms of gallbladder problems, or significant dehydration from prolonged vomiting or diarrhoea.

Suspected side effects can be reported directly to the MHRA via the Yellow Card scheme, which exists precisely to capture real-world experience across the full dose range as use widens. Our prescribers are available seven days a week if a question comes up after you start treatment, reach the team through the contact page.

If you are ready to talk through whether Wegovy is appropriate for you and which dose range makes clinical sense for your situation, start your free consultation with our GPhC-registered prescribers.